Jopamiro (Iopamidol)

Iopamidol contains a high concentration of iodine atoms that absorb X‑ray photons. When injected, the iodine increases the radiodensity of blood and extracellular fluid, creating a temporary contrast between tissues. This difference allows imaging equipment to produce sharper, more detailed pictures of anatomical structures.

The dose of Jopamiro is determined by the prescribing clinician based on the specific imaging study, patient weight, renal function, and the route of administration. Healthcare professionals calculate the appropriate volume and concentration to achieve optimal contrast while minimizing risk.

Safety data for Iopamidol in pregnancy and lactation are limited. It should only be used when clearly needed and after a risk‑benefit assessment by the treating physician. Breastfeeding mothers should discuss potential exposure with their healthcare provider, as the drug may be excreted in milk.

To order Jopamiro, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Jopamiro (Iopamidol) is a non‑ionic, low‑osmolality iodinated contrast medium, offering a favorable safety profile compared with older high‑osmolality agents. It provides comparable image enhancement while reducing the incidence of discomfort and adverse renal effects, making it a preferred choice for many diagnostic imaging procedures.

Jopamiro should be stored at ambient temperature, preferably below 25 °C, in its original sealed container. Protect the solution from direct sunlight, moisture, and extreme temperature fluctuations. Do not freeze the product, and inspect the vial for particulate matter before use.

Jopamiro is administered by a qualified healthcare professional via intra‑articular, intrathecal, or intravenous injection, depending on the imaging study. The injection is typically performed using a sterile technique, and the volume is adjusted to the specific diagnostic requirement and patient characteristics.

The most serious risks include severe allergic reactions such as anaphylaxis, contrast‑induced nephropathy leading to acute kidney injury, and rare cardiac events like arrhythmias or hypotensive shock. Patients with known iodine allergy, impaired renal function, or uncontrolled thyroid disease should be closely monitored.

Jopamiro should be avoided in individuals with a documented severe hypersensitivity to iodinated contrast media, uncontrolled hyperthyroidism, or severe renal impairment where alternative imaging methods are feasible. Pregnant or breastfeeding women should only receive it when the diagnostic benefit outweighs potential risks.